Healthcare Services

Fecal Transplant Therapy Market Size Forecast To Achieve $2.86 Billion By 2030 With 5.9% CAGR

May 28, 2026May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Fecal Transplant Therapy Market Over The Forecast Period?

The fecal transplant therapy market has shown significant expansion over recent years. This market is set to expand from $2.15 billion in 2025 to $2.28 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Key contributors to its historical growth include the documented effectiveness in treating recurrent CDI, increasing awareness among hospitals regarding microbiome therapies, the broadening of gastroenterology specialty services, the availability of basic stool preparation technologies, and early-stage clinical trials.

The market for fecal transplant therapy is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.87 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.9%. Several factors are contributing to this projected growth, including a wider range of disease indications, a heightened need for regulated and standardized products, the expansion of outpatient FMT procedures, increasing investment in microbiome therapeutics, and improvements in automated stool processing systems. Key trends expected during the forecast period involve the growing clinical acceptance of stool-based therapies, an increase in the development of capsule and suspension formats, a broader investigation into neurological and metabolic indications, the expansion of in-hospital FMT programs, and a stronger focus on safety and standardization.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19431&type=smp

Which Drivers Are Advancing The Fecal Transplant Therapy Market Growth?

The rising incidence of inflammatory bowel disease is anticipated to drive the future expansion of fecal transplant therapy markets. Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract, encompassing conditions such as Crohn’s disease and ulcerative colitis. The increase in IBD cases is attributed to factors like heightened consumption of highly processed foods, frequent or inappropriate antibiotic use, improved hygiene, and reduced exposure to infectious agents during childhood. Fecal transplant therapy aims to restore a healthy gut microbiota, which assists in mitigating inflammation and improving symptoms for patients with inflammatory bowel disease, potentially influencing its management and progression. For instance, in June 2023, Crohn’s and Colitis Canada, a Canada-based non-profit organization, reported that there will be 470,000 inflammatory bowel disease (IBD) sufferers in Canada by 2035, marking an increase from an estimated 322,600 in 2023. Consequently, the increasing prevalence of inflammatory bowel disease is propelling the growth of the fecal transplant therapy market.

What Key Segment Areas Are Included In The Fecal Transplant Therapy Market Assessment?

The fecal transplant therapy market covered in this report is segmented –

1) By Procedure: Fecal Enema, Fecal Bacteriotherapy, Stool Transplant, Human Probiotic Infusion, Fecal Transfusion

2) By Disease: Clostridium Difficile Infection, Autism, Obesity, Parkinson’s Disease (PD), Diabetes Mellitus, Other Diseases

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Fecal Enema: Retention Enema, Cleansing Enema, Retention-Based Fecal Transplants, Home Administration Kits

2) By Fecal Bacteriotherapy: Suspension-Based Bacteriotherapy, Capsule Formulations, Customized Bacterial Preparations, Single Strain vs. Multi-Strain Products

3) By Stool Transplant: Direct Stool Transplant Procedures, Stool Suspension Transplant, Stool Capsule Transplant, Automated Stool Preparation Systems

4) By Human Probiotic Infusion: Single-Strain Probiotic Infusions, Multi-Strain Probiotic Infusions, Probiotic Blends With Prebiotics, Infusion Kits for Healthcare Providers

5) By Fecal Transfusion: Intravenous Fecal Transfusion, Transfusion via Gastrostomy Tube, Pre-Packaged Fecal Transfusion Solutions, Fecal Transfusion For Research Purposes

Which Trends Are Expected To Shape The Fecal Transplant Therapy Market?

Leading companies in the fecal transplant therapy market are focusing on developing innovative treatments, such as oral pill forms of fecal microbiota transplantation (FMT) therapy, to enhance patient compliance and broaden access to the therapy. This pill form of fecal microbiota transplantation (FMT) therapy consists of encapsulated live bacteria sourced from donor feces, designed for oral administration. Its objective is to replenish healthy gut bacteria and improve intestinal health. For instance, in April 2023, Seres Therapeutics Inc., a US-based biotechnology company, and Nestlé Health Science S.A., a Switzerland-based healthcare company, introduced VOWST. It is provided in capsule form, presenting a convenient and less invasive treatment option to prevent recurrent clostridioides difficile infection (rCDI) in adults following antibacterial treatment. Unlike traditional fecal microbiota transplantation (FMT), which involves transferring whole stools, VOWST utilizes live bacterial spores of multiple Firmicute species derived from the fecal microbiota of healthy human donors, believed to restore the gut microbiome.

Which Key Players Are Active In The Fecal Transplant Therapy Market?

Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children’s Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women’s Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California

Access The Complete Fecal Transplant Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/fecal-transplant-therapy-global-market-report

Which Region Accounts For The Highest Share Of The Fecal Transplant Therapy Market?

North America was the largest region in the fecal transplant therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal transplant therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Fecal Transplant Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=19431&type=smp

Browse Through More Reports Similar to the Global Fecal Transplant Therapy Market 2026, By The Business Research Company

Genes Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Oligonucleotides Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Stem Cells Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795